Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small moleculesXin Lin, Hua Xiang, Xiang Lu et al.|European Journal of Medicinal Chemistry|2019Cited by 147
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistanceXin Lin, Guoshun Luo, Hua Xiang|European Journal of Medicinal Chemistry|2020Cited by 90
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivoGuoshun Luo, Hua Xiang, Zhenbang Li et al.|Acta Pharmaceutica Sinica B|2020Cited by 77
Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted DegradationGuoshun Luo, Hua Xiang, Carlos A. Velázquez‐Martínez et al.|Journal of Medicinal Chemistry|2021Cited by 49
Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2Xinyu Li, Hua Xiang, Cheng-Zhe Wu et al.|European Journal of Medicinal Chemistry|2018Cited by 33